Claims

1. An antibody, characterized in that the antibody is BAT4306F antibody, wherein the BAT4306F antibody is an anti-CD20 antibody that comprises two light chains each comprising the amino acid sequence of SEQ ID NO: 20 and two heavy chains each comprising the amino acid sequence of SEQ ID NO: 21, and wherein the BAT4306F antibody has a G0 content that is greater than or equal to 60% and has no fucose.

2. The antibody of claim 1, wherein the antibody has a mannose content that is less than or equal to 5%.

3. The antibody of claim 1 or 2, wherein the antibody has a high mannose content that is less than or equal to 5%.

4. A pharmaceutical composition, comprising the antibody according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier.

5. Use of the antibody according to any one of claims 1 to 3 or the pharmaceutical composition of claim 4 in the manufacture of a medicament for treating a disease, wherein the disease is responsive to antibody binding to CD20.

6. The use of claims 5, wherein the disease is Non-Hodgkin Lymphoma (NHL).

7. Use of the antibody according to any one of claims 1 to 3 or the pharmaceutical composition of claim 4 in the manufacture of a medicament for treating Non-Hodgkin Lymphoma (NHL).